Synairgen nyse. The market capitalisation of Synairgen is £7.

Synairgen nyse Learn more about Synairgen plc (SNG). SYNAIRGEN PLC SNG Company page - Search stock, chart, recent trades, company information, trading information, company news, fundamentals SNG | Complete Synairgen PLC stock news by MarketWatch. It has a market capitalisation of £25. Crossing Session orders will be accepted beginning at 1:00 p. Register for an account to get ideas, ask questions or join the conversation. L) stock quote, history, news and other vital information to help you with your stock trading and investing. MSCFFSFMMFISEFF (END) Dow Jones Newswires. Southampton, UK – 17 April 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, will announce its preliminary statement of audited results for the year ended 31 December 2022 on Thursday 27 April 2023. 10b shares in issue. The Company's primary focus is developing SNG001 (inhaled interferon beta) for the treatment of severe viral lung infections, including COVID-19, as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the Synairgen plc (‘Synairgen’ or the ‘Company’) Exercise of Share Options and Total Voting Rights. 63 million. From their employee growth over the years and their exchange listings. F: OTCPK RNS Number : 7084F. 07) This information is provided by RNS, the news service of the London Stock Exchange. 90 . X. Subject to regulatory approvals, Synairgen plans to initiate a Phase 2 clinical trial (SG021) in mechanically ventilated patients with confirmed respiratory viral infections during the coming 2024/2025 virus season. Southampton, UK - 29 September 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, This information is provided by RNS, the news service of the London Stock Exchange. To participate in the Open Offer, please contact Synairgen’s registrar, Link Group, at operationalsupportteam@linkgroup. 40p. CNBC is the world leader in business news and real-time financial market coverage. Products. The stock symbol for Synairgen is "SYNG. Synairgen PLC 1. The company noted that it had made p Synairgen plc (LON: SNG) shares fell 28. Synairgen - a potential cure for Covid 19? 24,192: 24/04/2024: 07:14: PBB: WatchOoT fer pump&dump merchants: 137: 07/02/2024: 14:47: PBB: Synairgen to present 60 and 90-day Long COVID data from Phase 3 SPRINTER study in hospitalised COVID-19 patients at IDWeek 2022 This information is provided by RNS, the news service of the London Stock Exchange. Synairgen is listed in the Medicine and Biotech sector. 00 a. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the Synairgen is a University spin-off and public limited company (plc) [2] [1] [3] working in drug discovery and biotechnology. 50 million. 5233429 | Site by Ether Reports & Statements Reports & Accounts Interim Statements. Get a brief overview of SYNAIRGEN ORD GBP0. It has a market capitalisation of Find the latest Synairgen plc (SNG. An event changing the breakdown of voting rights. Synairgen began a placebo-controlled Phase 2 trial in COVID-19 patients in the UK in March 2020. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19 · Fewer participants treated with SNG001 compared to placebo progressed to hospitalisation (1/110 vs 7/110, P=0. During the last trading day the stock fluctuated 10. Synairgen is a specialist respiratory biotech company whose primary focus is developing its investigative inhaled IFN-β candidate for the treatment of severe viral lung infections as potentially Southampton, UK – 29 June 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that at its Annual General Meeting, taking place today at 10am BST at Numis, 45 Gresham Street, London EC2V 7BF, the leadership team will Read today's most read article on London Stock Exchange and browse the most popular articles, to stay informed on all the top news of today. For further enquiries, please contact: Synairgen plc : Kurs, Charts, Kurse, Empfehlungen, Fundamentaldaten, Echtzeitnews und Analysen Aktie Synairgen plc | SNG | GB00B0381Z20 | London Stock Exchange * Each market will close early at 1:00 p. News Ideas Discussions Technicals Forecast Seasonals . 86 million. Southampton, UK - 22 June 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that on 21 June Synairgen (LSE: SNG) ("Synairgen", the "Company" and, together with its subsidiary undertakings, the "Group"), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that it has conditionally raised £18. Synairgen plc (‘Synairgen’ or the ‘Company’) Results for the year ended 31 December 2023. Synairgen is a UK-based respiratory company focused on drug discovery and the development of RNS Number : 2313H Synairgen plc 05 April 2022 . Add to Watchlist. Is Synairgen a Good Stock to Buy? Determining whether Synairgen—or any stock—is a good buy requires comprehensive analysis. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the Synairgen plc ('Synairgen' or the 'Company') Synairgen announces its collaboration on the UNIVERSAL trial, an observational study of patients hospitalised due to a range of respiratory viruses This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. 55p. Find fast, actionable information. London. 13% after releasing the final results for the year ended 31 December 2022. Our regions . Invest in Synairgen, London Stock Exchange AIM: SNG Stock - View real-time SNG price charts. TradingHours. 60p. RNS is approved by the Synairgen PLC. AIM:SNG Stock Report. All Rights ReservedRegistered in England and Wales No. Synairgen currently has 202,660,697 shares in issue. See on Supercharts. 475p, 12-month range 2. 04 RNS Number : 4597T. Southampton, UK – 26 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the Search stock, chart, recent trades, company information, trading information, company news, fundamentals 985 subscribers in the synairgen community. These cookies collect information, including analytics, about how you use our Services. The last closing price for Synairgen was 1. 80% on the last trading day (Wednesday, 22nd Jan 2025), rising from 1. Host Directed is Synairgen's new podcast series that explores the need for broad-spectrum antivirals to treat severe respiratory infections. View the latest SNG income statement, balance sheet, and financial ratios. Company Overview; (London Stock Exchange AIM Market)Yes: Ordinary Shares: GB: GBP: Oct 2004: SYGG. RNS is approved by the Financial Conduct Authority to act as a The latest Synairgen (SNG) ORD GBP 0. 8975p to 10. RNS is approved by the Financial Conduct Authority to act as a View the latest Synairgen PLC (SNG) stock price, decliners and most actives market activity tables are a combination of NYSE, Nasdaq, NYSE American and NYSE Arca listings. 58p. S. Synairgen's primary focus is the development of its investigational inhaled interferon beta product SNG001 to meet the significant unmet need for the treatment of severe viral lung infections in mechanically ventilated patients as Synairgen PLC (OTC:SYGGF) investor relations materials: earnings calls, slides & pdfs, and letter to shareholders. For further information, please contact The proceeds will fund a Phase 2 trial of Synairgen's investigational drug, SNG001, targeting patients on mechanical ventilation due to severe respiratory viral infections. National S. Jody BrookesSVP, Synairgen stock price live, this page displays LON SYNG stock exchange data. Sources: FactSet Synairgen PLC. Interferon beta (IFN-β) is a naturally occurring protein, which orchestrates the body's antiviral responses. Martin Murphy appointed as Non-Executive Director 16th January 2025; Result of General Meeting and Total Voting Rights 16th January 2025; £18 million raised to fund Phase 2 Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. Over the last year Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. SNG:LSE. Other Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. Get real-time updates and live market data on NEPSE. Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2024. on 17 January 2025. View the SYNG premarket stock price ahead of the market session or assess the after hours quote. Joseph ColliverChief Financial Officer, Executive Director. View real-time stock prices and stock quotes for a full financial overview. Discover the geographical origin of the shareholders of Synairgen plc. Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. on 5 November 2024. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate) Non-UK issuer. Our regions. Richard MarsdenChief Executive Officer, Executive Director. RNS is Track SYNAIRGEN ORD GBP0. 26 September 2024. Add to watchlist. 01 Application has been made to the London Stock Exchange for the 1,285,722 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8. Richard MarsdenChief Executive Officer, Executive Synairgen Company Description Synairgen plc discovers and develops drugs for respiratory diseases. Synairgen PLC + Add to watchlist + Add to portfolio + Add an alert. 22 June 2023 . Terms and conditions relating to the Thinking of buying or selling SYNAIRGEN PLC stock that’s listed in a currency different from your local one? Use our international stock ticker to check and convert stocks and shares easily in any currency you need. View SNG. Application has been made to the London Stock Exchange for the 1,285,722 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8. An acquisition or disposal of financial instruments. The London Stock Exchange > Pharmaceuticals & Biotechnology > Synairgen. There have not been any declared dividends recently. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the Synairgen is a UK-based respiratory company focused on drug discovery, development and commercialisation. Over the last year, Synairgen shares have traded in a share price range of 2. co. 17 Get Daily Technical Analysis of stock Synairgen with charts and key technical data RSI, MACD, Pivot points, Moving Averages, Buy/Sell signals. Latest Dividends. L. 29 million. g. This information is provided by RNS, the news service of the London Stock Exchange. Currency in GBP. Meetings with academic founders and other researchers, joint projects, and jointly written academic papers: Major suppliers: Regular project meetings where appropriate: Shareholders: Synairgen PLC + Add to watchlist + Add to portfolio + Add an alert. We set the standard with our unparalleled trading platform, enabling entrepreneurs, innovators, and Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price Sell candidate since Dec 12, 2024 Loss -59. Other View 2025 New York Stock Exchange (NYSE) Market Holidays, Trading Hours, Contact Information and more. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. Free Forums; Follow Feed; Brokers; PlusOneCoin; FTSE 100; Most Shorted Stocks; Education; Premium Forums; Newsletters; Bitcoin ETFs; Global Interest Rates; Sector Screener; Hot Features. Media@synairgen. UK financial statements in full. Financials . The market capitalisation of Synairgen is £4. The last closing price for Synairgen was 4. " What Stock Exchange Does Synairgen Trade On? Synairgen is listed and trades on the London stock exchange. for eligible options) on Thursday, July 3, 2025. Southampton, UK – 21 September 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta, today announces its Synairgen PLC balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. No trades. Jody BrookesSVP, Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. 2. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. 0 million Existing Ordinary Shares Search stock, chart, recent trades, company information, trading information, company news, fundamentals Synairgen plc ('Synairgen' or the 'Company') Board Changes. Over the last year, Synairgen shares have traded in a share price range of 3. 72p. Synairgen has also launched an open offer and placing to raise an additional £6 million, enabling existing shareholders to participate. uk. 00% Sector: Pharmaceuticals and Biotechnology Instrument: 1 Market cap: £5. LON. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover and New full-time role created as Synairgen progresses clinical development strategy; Southampton, UK – 3 October 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the immunomodulatory broad-spectrum antiviral protein interferon beta, today announces the appointment of Dr Marcin Mankowski as SNG Synairgen Plc Synairgen plc Adoption of FRS 101 - Reduced Disclosure Framework (8977F) The company news service from the London Stock Exchange. Southampton, UK – 27 June 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. Actions. The last closing price for Synairgen was 2. 80m, with approximately 1. 03%. m. 475p-7. The market capitalisation of Synairgen is £8. The business, focused primarily on severe asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic Key Opinion Leader network to discover Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. RNS Number : 0538U. Information collected includes, for example, the Internet browsers and operating systems used, the domain name of the website previously visited, the number of visits, average duration of visit, actions taken and pages viewed. The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. Terms and Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. Terms and conditions relating to the use and distribution of this information may apply. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. London Stock Exchange Oslo Børs Stockholmsbörsen Københavns Fondsbørs Investeringsforeninger Helsingin pörssi World Indices US Stocks US 30 Nasdaq 100 US 500 Toronto Stock Exchange London Stock Exchange Euronext Amsterdam Euronext Brussel DAX SDAX TECDAX Frankfurt CDAX MDAX Prime Standard CAC 40 Mumbai S. 08m Synairgen, furthermore, announces that, after 12 years of service, Iain Buchanan has retired from the Board and as Chair of the Remuneration and Nomination Committee. 75p. RNS is Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. Financial calendar reference data for enterprise TradingHours Terminal New. 1b. RNS . Overview The latest Synairgen Open Offer - Assented Line share price. Synairgen shall not be liable for any errors in this information or any delay in its The stock symbol for Synairgen is "SYNG. It develops SNG001, an inhaled interferon beta for the treatment of severe viral lung infections that is in pre- clinical trial; and inhaled interferon beta IFN-ß, a naturally occurring protein that helps regulate the immune system to fight viruses, including coronaviruses. stock exchange. United Kingdom; SNG:LSE London Stock Exchange; Germany; OMY:STU Stuttgart Stock OMY:BER Berlin Stock Exchange; United States; SYGGF:PKC OTC Pink - Current Information; Synairgen PLC. Synairgen SNG. Københavns Fondsbørs Investeringsforeninger Helsingin pörssi World Indices US Stocks US 30 Nasdaq 100 US 500 Toronto Stock Exchange London Stock Exchange Euronext Amsterdam Euronext Brussel Invest in Synairgen, London Stock Exchange AIM: SNG Stock - View real-time SNG price charts. Southampton, UK - 23 December 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein Synairgen Plc Ord 1p is listed on the London Stock Exchange trading with ticker code SNG. SYNAIRGEN PLC is a company listed and traded on the London Stock Exchange under SNG. Southampton, This information is provided by RNS, the news service of the London Stock Exchange. Southampton, UK - 25 May 2022: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, This information is provided by RNS, the news service of the London Stock Exchange. The Company is engaged in the drug discovery and development of therapies for respiratory diseases, particularly in the areas, including View 2025 New York Stock Exchange (NYSE) Market Holidays, Trading Hours, Contact Information and more. Market Cap: UK£3. for continuous executions until 1:30 p. Synairgen is a University spin-off and public limited company working in drug discovery and biotechnology. The market capitalisation of Synairgen is £7. Dividend Summary. Synairgen. (1:15 p. 54 million. Host Directed, broad-spectrum antivirals. Viruses have evolved mechanisms which suppress natural IFN-β production, thereby helping the virus evade the London Stock Exchange • delayed by 15 minutes • CURRENCY IN GBp • Biotechnology & Medical Research. Southampton, UK - 15 November 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, NYSE President Martin Says More Companies Are Pursuing U. Synairgen plc ('Synairgen' or the 'Company') Results from SPRINTER Phase 3 trial published in the European Respiratory Journal Open Research. In Episode 1, Not All Antivirals Are the Same, Professor Synairgen is a UK-based respiratory company focused on drug discovery and the development of SNG001 (inhaled interferon beta) as potentially the first host-targeted, broad-spectrum antiviral treatment delivered directly into the lungs for severe viral lung infections. Start your journey here Discover the world’s international exchange. CREST accounts of the investors in the Fundraising who hold their Ordinary Shares in CREST will be credited with their New Ordinary Synairgen expects to receive the Phase 2 data from ACTIV-2 in the first half of this year and will evaluate it alongside the full dataset from its SPRINTER trial to better understand the effects of SNG001 in patients at risk of developing severe illness due to respiratory viruses. RNS is Synairgen plc ('Synairgen' or the 'Company') Update on SNG001 in the ACTIV-2 Phase 3 trial for COVID-19 and on SNG001 activity against Delta and Omicron variants. The business, focused primarily on lung viral defence in asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover © Synairgen plc. 71p to a day high of 1. Synairgen plc ('Synairgen' or the 'Company') Posting of Annual Report and Accounts and Notice of Annual General Meeting. 8m. Select symbol. Terms and conditions relating Search stock, chart, recent trades, company information, trading information, company news, fundamentals synairgen plc sng synairgen plc ord 1p Explore more about this Issuer 2. Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company. Synairgen PLC (SNG) Compare. For further details, refer to PART IV of the Circular (page 49), including information on Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. Over the last year, Synairgen shares have traded in a share price Synairgen plc ('Synairgen' or the 'Company') Synairgen announces topline results from Phase 3 SPRINTER trial in patients hospitalised with COVID-19 . 99p. The price has been going up and down for this period, and there has been a -5. IPOs. Read today's most read article on London Stock Exchange and browse the most popular articles, to stay informed on all the top news of today. 2023 Annual Report 27th June 2024; 2022 Annual Report 22nd May 2023; 2021 Annual Report 6th June 2022; 2020 Annual Report 25th May 2021; 2019 Annual Report 3rd June 2020; 2018 Annual Report 18th April 2019; 2017 Annual Report 18th May 2018; 2016 Annual Report 5th June 2017; 2015 Annual Report Press View all press releases Subscribe to news 2025. Simply Wall St Financial Health Rating: ★★★★★☆ Overview: Synairgen plc focuses on discovering and developing drugs for respiratory diseases, with a market cap of £9. The market Die Synairgen PLCShs Aktie wird unter der ISIN GB00B0381Z20 an den Börsen Frankfurt, München, Stuttgart, Berlin, London, Nasdaq OTC, gettex und Baader Bank gehandelt. Get the latest Synairgen plc (SNG) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Synairgen plc. Chat About SNG Shares - Stock Quote, Charts, Trade History, Share Chat, Financial Terms Glossary. 25 million. Synairgen plc (‘Synairgen’ or the ‘Company’) Appointment of New Chairman. 01% loss for the Synairgen has developed SNG001, an inhaled formulation of IFN-β designed to directly target the lungs, the primary site of many viral lung infections. The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price Synairgen plc (‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2023. 01 stock price on the chart and check out the list of the most volatile stocks — is SYNAIRGEN ORD GBP0. Southampton, UK – 18 September 2024: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, announces that Simon Shaw * Each market will close early at 1:00 p. Should You Buy or Sell Synairgen Stock? Get The Latest SNG Stock Analysis, Price Target, Dividend Info, and Headlines at MarketBeat. What is the current performance of SNG. FTSE 100; Synairgen PLC, down 34% at 2. on that date, and NYSE American Equities, NYSE Arca Equities, NYSE Chicago, and NYSE National late trading sessions will close at 5:00 p. The last closing price for Synairgen was 3. Overview . 82% from a day low at 1. Powerful web-based terminal for traders Markets Synairgen is a drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price Search stock, chart, recent trades, company information, trading information, company news, fundamentals Synairgen plc ('Synairgen' or the 'Company') Results for the year ended 31 December 2021. The market capitalisation of Synairgen is £9,927,786. 01 market cap? Today SYNAIRGEN ORD GBP0. 01 there? What is SYNAIRGEN ORD GBP0. Synairgen plc ('Synairgen' or the 'Company') Grant of Options. Please note that the share price quoted on the London Stock Exchange website is delayed by 15 minutes. The Company is developing SYNAIRGEN PLC. 90p. 23p. 72p to 1. Powerful web-based terminal for traders Markets Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. Add to watchlist; Add to portfolio; Add an alert; Read today's most read article on London Stock Exchange and browse the most popular articles, to stay informed on all the top news of today. 01 share price (SNG). Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. Synairgen has a price to earnings ratio (PE ratio) of -1. Synairgen announces positive findings from analysis of lung samples from the SG015 trial of SNG001 in virally infected COPD patients. It is expected that Admission will become effective at 8. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics. 5233429 | Site by EtherRegistered in England and Wales No. Market closed Market closed. The Synairgen stock price gained 4. 56 GBX 2. 01 financials with all the important numbers. With Synairgen PLC. Market Holidays & Trading Hours API. Felicity ('Flic') Gabbay succeeds Iain as Chair of the Remuneration and Nomination Committee. 30p. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the Search stock, chart, recent trades, company information, trading information, company news, fundamentals Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. Reason for the notification (please mark the appropriate box or boxes with an "X") This information is provided by RNS, the news service of the London Stock Exchange. It was founded in Synairgen Plc (SNG) 2023年年度报告「LSE」. E. END. The directors are also required to prepare financial statements in accordance with the rules of the London Stock Exchange for companies Like other stocks, SNGL shares are traded on stock exchanges, e. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price RNS Number : 8865N Synairgen plc 06 June 2022. com. LON stock? As of 24-01 The NYSE is capitalism at its best, the belief that the free and fair markets offer every individual the chance to benefit from success. Terms and Thinking of buying or selling SYNAIRGEN PLC stock that’s listed in a currency different from your local one? Use our international stock ticker to check and convert stocks and shares easily in any currency you need. Southampton, England-based drug Welcome to the Stockopedia community's LON:SNG discussion board, with posts on SYNAIRGEN share news, analysis and share sentiment. Dashboard Portfolios Watchlist Community Discover Screener. Davies and Ratko Djukanovic [ Wikidata ] . Synairgen Share Chat. Inhaled IFN-β. Posting of Report and Accounts and Notice of AGM. Senior Management. 52 Synairgen plc ('Synairgen' or the 'Company') Synairgen presents detailed analysis of Phase 3 SPRINTER trial evaluating SNG001 in hospitalised COVID-19 patients at ATS 2022 This information is provided by RNS, the news service of the London Stock Exchange. 13% after Aquis Stock Exchange Share Prices; Euronext Share Prices; US Share Prices; UK Indices. Synairgen plc ('Synairgen' or the 'Company') This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. 85p. pdf，点击即可下载。 that period. 09p. Based on the results of the Phase 2 trial, the company initiated a Phase 3 trial in January 2021 which ultimately included 17 countries. Synairgen PLCShs ist ein Southampton, UK – 27 April 2023: Synairgen plc (LSE: SNG), the respiratory company developing SNG001, an investigational formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces its preliminary statement of audited results for the year ended 31 December 2022. It was founded in 2003 by University of Southampton professors Stephen Holgate , [ 4 ] Donna E. 00p to 10. To do this, you need to open an account and follow a broker's Led by a team of industry experts and world-renowned academics, Synairgen is dedicated to creating pandemic-ready respiratory treatments we can all believe in. November 16, 2015 11:11 ET (16:11 GMT) Synairgen (LSE:SNG) Historical Stock Chart From Nov 2024 to Dec 2024 Synairgen London Stock Exchange Oslo Børs Stockholmsbörsen Københavns Fondsbørs Investeringsforeninger Helsingin pörssi World Indices US Stocks US 30 Nasdaq 100 US 500 Toronto Stock Exchange London Stock Exchange Euronext Amsterdam Euronext Brussel DAX SDAX TECDAX Frankfurt CDAX MDAX Prime Standard CAC 40 Mumbai S. Over the last year, Synairgen shares have traded in a share price range of 1. . SNG001 has been tested in several clinical studies in both out-patient and hospital Synairgen is listed and trades on the London stock exchange. United Kingdom; Synairgen plc - SNG - Exercise of Share Options and Total Voting Rights. Summary Synairgen plc is a holding company. SNG fundamentals. NYSE is open M-F, 9:30 am - 4:00 pm (EST). Add to watchlist; Add to portfolio; Add an alert; Nepal Stock Exchange provides information on stock prices, company details, and financial reports. 23 SYNAIRGEN PLC LS-,01 Kurs heute • Aktuelle Realtime Finanzdaten, Nachrichten und Informationen zur Aktie (SNG) • GB00B0381Z20 (A0DK7J) • Gesundheit • Biotechnologie London Stock Exchange; Discover. Southampton, UK - 11 October 2023: Synairgen plc (LSE: SNG), the respiratory company Synairgen plc + 44 (0)23 8051 2800. A subreddit to share links relating to the inhaled Interferon Beta 1a drug 'SNG001', a broad spectrum Search stock, chart, recent trades, company information, trading information, company news, fundamentals Synairgen Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker SNG. Synairgen Plc Ord 1p is listed on the London Stock Exchange trading with ticker code SNG. Online commission-free investing in Synairgen: buy or sell Synairgen Stock commission-free with Trading 212. Find the distribution by types of shareholders of Synairgen plc listed on the London S. 01p to 10. Cavendish Capital Markets Limited -Nominated Adviser, joint broker and sole bookrunner + 44 (0)20 7220 0500 Synairgen collaborates closely with University of Southampton researchers, and has intellectual property licences and a facilities agreement in place with the University. 00p. Synairgen (LSE: SNG) Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Reason for the notification (please mark the appropriate box or boxes with an "X") An acquisition or disposal of voting rights. Synairgen plc ('Synairgen' or the 'Company') Appointment of Joseph Colliver as New Chief Financial Officer. SNG London Stock Exchange. Highlights (including post period-end) London Stock Exchange Oslo Børs Stockholmsbörsen Københavns Fondsbørs Investeringsforeninger Helsingin pörssi World Indices US Stocks US 30 Nasdaq 100 US 500 Toronto Stock Exchange London Stock Exchange Euronext Amsterdam Euronext Brussel DAX SDAX TECDAX Frankfurt CDAX MDAX Prime Standard CAC 40 Mumbai S. Discover . 04 The stock symbol for Synairgen is "SYNG. 80p. 27 June 2024. The market capitalisation of Synairgen is £9. 48 million. 15 November 2023 . Synairgen currently has 201,374,975 shares in issue. 62p. 18. The Synairgen plc (LON: SNG) share price fell 28. 71p. Discover. LON stock? As of 23-01 RNS Number : 5144D. zrkhjz rmr jfl yntqewde yfpy fnqa xgxqgdn uxbuq uychza oug